Women at Risk for Gonorrhea: Comparison of Rosaramicin and Ampicillin plus Probenecid in the Eradication of Neisseria gonorrhoeae, Chlamydia trachomatis and Genital Mycoplasmas

Rosaramicin is a macrolide antibiotic with activity against Neisseria gonorrhoeae, Chlamydia trachomatis, and the genital mycoplasmas Ureaplasma urealyticum and Mycoplasma horninis. Its efficacy in the treatment of genital infections was evaluated and compared with that of single-dose ampicillin plu...

Full description

Saved in:
Bibliographic Details
Published in:Sexually transmitted diseases 1985-01, Vol.12 (1), p.1-4
Main Authors: BATTEIGER, BYRON E., ZWICKL, BETH E. WALTERS, FRENCH, MORRIS L. V., JONES, ROBERT B.
Format: Article
Language:English
Subjects:
Adolescent
Adult
Ampicillin - therapeutic use
Chlamydia Infections - drug therapy
Chlamydia trachomatis
Clinical Trials as Topic
Double-Blind Method
Drug Combinations
Female
Gonorrhea - drug therapy
Humans
Leucomycins - therapeutic use
Mycoplasma Infections - drug therapy
Original Articles
Probenecid - therapeutic use
Random Allocation
Risk
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Rosaramicin is a macrolide antibiotic with activity against Neisseria gonorrhoeae, Chlamydia trachomatis, and the genital mycoplasmas Ureaplasma urealyticum and Mycoplasma horninis. Its efficacy in the treatment of genital infections was evaluated and compared with that of single-dose ampicillin plus probenicid in women with known, or suspected, uncomplicated gonococcal infection. Isolation rates for N. gonorrhoeae, trachomatis, U. urealyticum, and M. hominis were 72%, 44%, 95%, and 65%, respectively. Rosaramicin cured 24 (89%) of 27 gonococcal infections and 11 (92%) of 12 chlamydial infections. It transiently reduced the carriage of U. urealyticum but had little effect on carriage of M. hominis. Rosaramicin may be of value in the treatment of concurrent gonococcal and chlamydial infections when tetracycline is contraindicated.
ISSN:0148-5717
1537-4521
DOI:10.1097/00007435-198501000-00001